Pluri Inc. Debt Related Commitment Fees and Debt Issuance Costs
Pluri Inc. (PLUR) reported Debt Related Commitment Fees and Debt Issuance Costs of $445.00 thousand for the 9-month period ending 2023-03-31, per its 10-K filed 2023-09-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2024-09-18
- Pluri Inc. debt related commitment fees and debt issuance costs for the quarter ending 2023-03-31 was $0.00.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs 3 month | Debt Related Commitment Fees and Debt Issuance Costs 6 month | Debt Related Commitment Fees and Debt Issuance Costs 9 month | Debt Related Commitment Fees and Debt Issuance Costs 9 month as first filed |
|---|---|---|---|---|
| 2023-03-31 | $0.00 derived: 10-K 9 month − 10-K 6 month · filed 2023-09-12 | $445.00K 10-K · filed 2023-09-12 | $435.00 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $445.00K 10-K · filed 2024-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |